ROS1 and non-small cell lung carcinoma: Using the SP142 antibody with the cutoff of ≥1% and ≥50% for TPS, and at ≥1% and ≥10% for immune proportion score (IPS), PD-L1 was correlated negatively with EGFR mutations and positively with KRAS, BRAF, and MET mutations and ROS1 translocations, in Chinese NSCLC patients [11].